

Amendments to Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-35. (Canceled)

36. (Currently amended) An orally administrable liquid dosage formulation comprising (i) 1 milligram to 25 milligrams donepezil or a pharmaceutically acceptable salt thereof; (ii) 0.5 to 2% by weight of a polyvinylpyrrolidone having an average molecular weight of 10,000 to 100,000; (iii) 30 to 40% by weight of a 70% w/w sorbitol solution; (iv) citric acid and sodium citrate in a combined amount of 0.05 to 3% by weight; (v) sodium benzoate and methylparaben in a combined amount of 0.05 to 1% by weight; (vi) 3 to 9% by weight propylene glycol; (vii) 0.01 to 0.1% by weight sodium metabisulfite; and (viii) 0.1 to 1% by weight of a flavoring agent, wherein the formulation has a pH from 6.5 to 9.

37. (Previously Presented) The formulation of claim 36, comprising 5 milligrams to 10 milligrams donepezil hydrochloride.

38. (Cancelled)

39. (Previously Presented) The formulation of claim 36 having a pH from 7 to 8.5.

40. (Previously Presented) The formulation of claim 36, wherein the polyvinylpyrrolidone has an average molecular weight of 40,000.

41. (Previously Presented) The formulation of claim 36, wherein the donepezil is in the form of the R-stereoisomer or the S-stereoisomer.

42. (Currently amended) An orally administrable liquid dosage formulation comprising (i) 1 milligram to 25 milligrams donepezil or a pharmaceutically acceptable salt thereof; (ii) 0.1 to 3% by weight of a polyvinylpyrrolidone having an average molecular weight of 10,000 to 100,000; (iii) 25 to 45% by weight of a 70% w/w sorbitol solution; (iv) citric acid and sodium citrate in a combined amount of 0.01 to 5% by weight; (v) sodium benzoate and methylparaben in a combined amount of 0.01 to 3% by weight; (vi) 1 to 10% by weight propylene glycol; (vii) 0.001 to 1% by weight sodium metabisulfite; and (viii) 0.01 to 3% by weight of a flavoring agent, wherein the formulation has a pH from 6.5 to 9.

43. (Previously Presented) The formulation of claim 42, comprising 5 milligrams to 10 milligrams donepezil hydrochloride.

44. (Cancelled)

45. (Previously Presented) The formulation of claim 42 having a pH from 7 to 8.5.

46. (Previously Presented) The formulation of claim 42, wherein the polyvinylpyrrolidone has an average molecular weight of 40,000.

47. (Previously Presented) The formulation of claim 42, wherein the donepezil is in the form of the R-stereoisomer or the S-stereoisomer.

48. (Currently amended) An orally administrable liquid dosage formulation comprising (i) 1 milligram to 25 milligrams donepezil or a pharmaceutically acceptable salt thereof; (ii) 0.1 to 3% by weight of a polyvinylpyrrolidone having an average molecular weight of 10,000 to 100,000; (iii) 25 to 45% by weight of a 70% w/w sorbitol solution; (iv) 0.01 to 5% by weight of at least one pH adjusting agent; (v) 0.01 to 3% by weight of at least one preservative; (vi) 1 to 10% by weight of at least one solvent; (vii) 0.001 to 1% by weight of at least one antioxidant; and (viii) 0.01 to 3% by weight of a flavoring agent, wherein the formulation has a pH from 6.5 to 9.

49. (Previously Presented) The formulation of claim 48, wherein the pH adjusting agent is selected from the group consisting of citric acid, sodium citrate, adipic acid, sodium bicarbonate, sodium hydroxide, hydrochloric acid, lactic acid, and phosphoric acid.

50. (Previously Presented) The formulation of claim 48, wherein the preservative is selected from the group consisting of sodium benzoate, methylparaben, propylparaben, butylparaben, ethylparaben, butylated hydroxanisole, butylated hydroxytoluene, and sorbic acid.

51. (Previously Presented) The formulation of claim 48, wherein the solvent is selected from the group consisting of propylene glycol, alcohol, and glycerin.

52. (Previously Presented) The formulation of claim 48, wherein the antioxidant is selected from the group consisting of sodium metabisulfite, sodium sulfite, sodium bisulfite, sodium thiosulfate, and ascorbic acid.

53. (Cancelled)

54. (Previously Presented) The formulation of claim 48 having a pH from 7 to 8.5.

55. (Previously Presented) The solution of claim 48, wherein the donepezil is in the form of the R-stereoisomer or the S-stereoisomer.